That’s why I Feel Comfortable With Cytek BioSciences Inc’s (CTKB) Future

Currently, Cytek BioSciences Inc [CTKB] is trading at $5.11, up 3.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CTKB shares have gain 8.96% over the last week, with a monthly amount drifted -0.58%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Cytek BioSciences Inc [NASDAQ: CTKB] stock has seen the most recent analyst activity on December 14, 2023, when Stephens initiated its Overweight rating and assigned the stock a price target of $9.

This stock has fluctuated between a low of $3.80 and a high of $9.87 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Cytek BioSciences Inc [NASDAQ: CTKB] shares were valued at $5.11 at the most recent close of the market. An investor can expect a potential return of 66.34% based on the average CTKB price forecast.

Analyzing the CTKB fundamentals

Trailing Twelve Months sales for Cytek BioSciences Inc [NASDAQ:CTKB] were 197.71M which represents -6.19% decline. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.04 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.96 points at the first support level, and at 4.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.24, and for the 2nd resistance point, it is at 5.38.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Cytek BioSciences Inc [NASDAQ:CTKB] is 7.33. As well, the Quick Ratio is 6.38, while the Cash Ratio is 3.4. Considering the valuation of this stock, the price to sales ratio is 3.51, the price to book ratio is 1.73.

Transactions by insiders

Recent insider trading involved Yan Ming, CHIEF TECHNOLOGY OFFICER, that happened on Apr 19 ’24 when 20000.0 shares were sold. CHIEF TECHNOLOGY OFFICER, Yan Ming completed a deal on Apr 09 ’24 to sell 1900.0 shares. Meanwhile, CHIEF TECHNOLOGY OFFICER Yan Ming sold 20000.0 shares on Mar 18 ’24.

Related Posts